Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04082780 · ClinicalTrials.gov registry record · Phase 2
Rifamycin in Minimal Hepatic Encephalopathy
A Phase 2 study, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT04082780 is a Phase 2 study that has completed, run by Hunter Holmes Mcguire Veteran Affairs Medical Center. The registered enrollment target is 30 participants.
The verdict
NCT04082780, a Phase 2 study, has completed, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
Interventions
- OTHER Placebo
- DRUG Rifamycin SV MMX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2023-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04082780
The ClinicalTrials.gov registry entry for NCT04082780 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04082780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04082780 about?
NCT04082780 is a clinical study titled "Rifamycin in Minimal Hepatic Encephalopathy". This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
What is the current status of trial NCT04082780?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-09-01. Estimated completion is 2023-04-28.
What interventions are being tested in trial NCT04082780?
The interventions under investigation include: Placebo (OTHER), Rifamycin SV MMX (DRUG).
Who is sponsoring clinical trial NCT04082780?
This trial is sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.